PRESS RELEASE
02 November 2022 08:45:00 CET

ALLIGATOR BIOSCIENCE ANNOUNCES PUBLICATION HIGHLIGHTING BISPECIFIC ANTIBODIES TARGETING CD40 AND TUMOR ANTIGENS IN PEER-REVIEWED JOURNAL FOR IMMUNOTHERAPY OF CANCER

- **Article shows CD40 x TAA bispecific antibodies can induce enhanced T cell cross-priming superior to monospecific CD40 antibodies using *in vivo* models**
- **This concept translates into superior anti-tumor effects compared to monospecific CD40 antibodies and induces T cell-dependent anti-tumor memory**

Lund, Sweden, November 2, 2022 - Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced the publication of a peer-reviewed article highlighting how bispecific Neo-X-Prime™ antibodies targeting CD40 and tumor-associated antigens (TAA) represent a promising novel treatment modality with the potential to meet key needs in immuno-oncology.

The publication in the *Journal for ImmunoTherapy of Cancer* demonstrates how Alligator´s Neo-X-Prime™ platform can be used to generate 3rd generation bispecific antibodies with significantly superior anti-tumor effect to the monospecific CD40 antibodies. The results of the study also demonstrated *in vitro* that the antibodies induced clustering of tumor debris and CD40-expressing cells in a dose-dependent manner and superior T cell priming when added to dendritic cells, and antigen-containing tumor debris or exosomes. Further, the data show that the CD40 x TAA bispecific antibodies induced TAA-conditional CD40 activation both *in vitro* and *in vivo* , which shows the potential for a wide therapeutic window for Neo-X-Prime™ bispecific antibodies.

The full article, entitled ***"Bispecific antibodies targeting CD40 and tumor associated antigens promote cross-priming of T cells resulting in an anti-tumor response superior to monospecific antibodies"***, is available in print and online via **this link**.

The publication of our peer-reviewed study in this renowned scientific journal is a welcome endorsement of the work we are undertaking at Alligator on bispecific CD40 antibodies," said **Peter Ellmark, CSO of Alligator Bioscience and one of the study's authors.** *"The mechanism we describe demonstrates these antibodies provide a new opportunity to enhance cross-priming of T cells, which has the potential to meet key needs in immuno-oncology by increasing the quantity and quality of tumor specific T cells, while at the same time remodelling*

the tumor microenvironment through myeloid cell activation to allow for more efficient treatment of cancer patients.

We are very pleased to see further data supporting our novel Neo-X-Prime approach, which simultaneously targets CD40 and tumor associated antigens leading to superior anti-tumor immunity," said **Søren Bregenholt, PhD, CEO of Alligator Bioscience.** *"Being more efficient and safer compared to existing monospecific therapies, Neo-X-Prime represents a promising new therapeutic tool in immuno-oncology, and we are progressing with the development of our preclinical first-in-class bispecific CD40 agonist, ATOR-4066, for which we see medical opportunities in multiple cancer indications.*

The information was submitted for publication, through the agency of the contact persons set out below, at 08:45 a.m. CET on November 2, 2022.

For further information, please contact:

Søren Bregenholt, CEO
E-mail: **soren.bregenholt@alligatorbioscience.com**
Phone: +46 (0) 46 540 82 00

LifeSci Advisors
Investor Relations
Guillaume van Renterghem
E-mail: **gvanrenterghem@lifesciadvisors.com**
Phone: +41 (0) 76 735 01 31

PRESS RELEASE
02 November 2022 08:45:00 CET

About Alligator Bioscience

Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator's pipeline includes the two key assets mitazalimab, a CD40 agonist, and ATOR-1017, a 4- 1BB agonist. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its proprietary technology platform, Neo-X-Prime™, and novel drug candidates based on the RUBY™ bispecific platform with Orion Corporation. Out-licensed programs include AC101/HLX22, in Phase 2 development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc.

Alligator Bioscience's shares are listed on Nasdaq Stockholm (ATORX) and is headquartered in Lund, Sweden.

For more information, please visit **alligatorbioscience.com**.

Attachments

Alligator Bioscience Announces Publication Highlighting Bispecific Antibodies Targeting CD40 and Tumor Antigens in Peer-Reviewed Journal for ImmunoTherapy of Cancer